Biovail Locks Up Global Rights To Xenazine With Cambridge Deal
The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.
The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.